Anupam Rama
Stock Analyst at JP Morgan
(4.36)
# 376
Out of 5,081 analysts
292
Total ratings
49.38%
Success rate
19.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Maintains: Underweight | $7 → $6 | $6.84 | -12.28% | 1 | Nov 18, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $17 → $20 | $10.98 | +82.15% | 7 | Nov 18, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $29 → $32 | $27.25 | +17.43% | 6 | Nov 18, 2025 | |
| ENTA Enanta Pharmaceuticals | Initiates: Overweight | $17 | $14.24 | +19.38% | 1 | Nov 14, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $40 → $33 | $19.71 | +67.43% | 11 | Nov 12, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $55 → $57 | $32.06 | +77.82% | 10 | Nov 12, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $53 → $52 | $41.26 | +26.03% | 11 | Nov 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $26 → $27 | $8.31 | +224.91% | 5 | Nov 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $76 → $77 | $74.15 | +3.84% | 12 | Nov 7, 2025 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $18 → $19 | $9.78 | +94.27% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $11 | $5.19 | +111.95% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $36 | $21.25 | +69.41% | 18 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $171 → $179 | $151.96 | +17.79% | 19 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $22.96 | +4.53% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $34.34 | +130.05% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $44 | $39.16 | +12.36% | 8 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 | $10.32 | +6.59% | 12 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $220.98 | -9.49% | 1 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $37 | $41.49 | -10.82% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.25 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $21.84 | +9.89% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $43.76 | +82.82% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $36.45 | +220.99% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $19.75 | +158.23% | 12 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $34.85 | +26.26% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $40.61 | -1.50% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $106.90 | +16.93% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.46 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.66 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.00 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.28 | +203.74% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $90 | $5.23 | +1,620.84% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $12.55 | +1,892.03% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.55 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $64.66 | -10.30% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $18.90 | -36.51% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $6.27 | +490.11% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $86.07 | -36.10% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $3.29 | +751.06% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $27.49 | +96.44% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.83 | +5,346.62% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $20.09 | +34.40% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $473.29 | -71.05% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $7.79 | +516.17% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.97 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.02 | +2,841.18% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $75.76 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.73 | - | 2 | Jul 21, 2017 |
Novavax
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $6.84
Upside: -12.28%
ORIC Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $10.98
Upside: +82.15%
Olema Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $29 → $32
Current: $27.25
Upside: +17.43%
Enanta Pharmaceuticals
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $14.24
Upside: +19.38%
Syndax Pharmaceuticals
Nov 12, 2025
Maintains: Overweight
Price Target: $40 → $33
Current: $19.71
Upside: +67.43%
RAPT Therapeutics
Nov 12, 2025
Maintains: Overweight
Price Target: $55 → $57
Current: $32.06
Upside: +77.82%
Vera Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $41.26
Upside: +26.03%
Day One Biopharmaceuticals
Nov 7, 2025
Maintains: Overweight
Price Target: $26 → $27
Current: $8.31
Upside: +224.91%
BridgeBio Pharma
Nov 7, 2025
Maintains: Overweight
Price Target: $76 → $77
Current: $74.15
Upside: +3.84%
Amicus Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $9.78
Upside: +94.27%
Nov 5, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $5.19
Upside: +111.95%
Nov 5, 2025
Maintains: Overweight
Price Target: $40 → $36
Current: $21.25
Upside: +69.41%
Nov 3, 2025
Maintains: Overweight
Price Target: $171 → $179
Current: $151.96
Upside: +17.79%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $22.96
Upside: +4.53%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $34.34
Upside: +130.05%
Oct 21, 2025
Maintains: Overweight
Price Target: $30 → $44
Current: $39.16
Upside: +12.36%
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $10.32
Upside: +6.59%
Oct 10, 2025
Initiates: Overweight
Price Target: $200
Current: $220.98
Upside: -9.49%
Sep 29, 2025
Maintains: Overweight
Price Target: $27 → $37
Current: $41.49
Upside: -10.82%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.25
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $21.84
Upside: +9.89%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $43.76
Upside: +82.82%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $36.45
Upside: +220.99%
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $19.75
Upside: +158.23%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $34.85
Upside: +26.26%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $40.61
Upside: -1.50%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $106.90
Upside: +16.93%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.46
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.66
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $4.00
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.28
Upside: +203.74%
Aug 16, 2023
Maintains: Neutral
Price Target: $80 → $90
Current: $5.23
Upside: +1,620.84%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $12.55
Upside: +1,892.03%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $8.55
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $64.66
Upside: -10.30%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $18.90
Upside: -36.51%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $6.27
Upside: +490.11%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $86.07
Upside: -36.10%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $3.29
Upside: +751.06%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $27.49
Upside: +96.44%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.83
Upside: +5,346.62%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $20.09
Upside: +34.40%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $473.29
Upside: -71.05%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $7.79
Upside: +516.17%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $10.97
Upside: -
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.02
Upside: +2,841.18%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $75.76
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.73
Upside: -